Literature DB >> 32869871

Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Yunping Deng1, Hongbing Wang1, Marion Joni1, Radhika Sekhri2, Anton Reiner1,3.   

Abstract

We used behavioral testing and morphological methods to detail the progression of basal ganglia neuron type-specific pathology and the deficits stemming from them in male heterozygous Q175 mice, compared to age-matched WT males. A rotarod deficit was not present in Q175 mice until 18 months, but increased open field turn rate (reflecting hyperkinesia) and open field anxiety were evident at 6 months. No loss of striatal neurons was seen out to 18 months, but ENK+ and DARPP32+ striatal perikarya were fewer by 6 months, due to diminished expression, with further decline by 18 months. No reduction in SP+ striatal perikarya or striatal interneurons was seen in Q175 mice at 18 months, but cholinergic interneurons showed dendrite attenuation by 6 months. Despite reduced ENK expression in indirect pathway striatal perikarya, ENK-immunostained terminals in globus pallidus externus (GPe) were more abundant at 6 months and remained so out to 18 months. Similarly, SP-immunostained terminals from striatal direct pathway neurons were more abundant in globus pallidus internus and substantia nigra at 6 months and remained so at 18 months. FoxP2+ arkypallidal GPe neurons and subthalamic nucleus neurons were lost by 18 months but not prototypical PARV+ GPe neurons or dopaminergic nigral neurons. Our results show that striatal projection neuron abnormalities and behavioral abnormalities reflecting them develop between 2 and 6 months of age in Q175 male heterozygotes, indicating early effects of the HD mutation. The striatal pathologies resemble those in human HD, but are less severe at 18 months than even in premanifest HD.
© 2020 The Authors. The Journal of Comparative Neurology published by Wiley Periodicals LLC.

Entities:  

Keywords:  Huntington's disease; Q175 mice; aggregates; basal ganglia; neuropathology

Mesh:

Year:  2020        PMID: 32869871      PMCID: PMC8049038          DOI: 10.1002/cne.25023

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  209 in total

1.  Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.

Authors:  K A Sieradzan; A O Mechan; L Jones; E E Wanker; N Nukina; D M Mann
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

Review 2.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

3.  Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.

Authors:  Susanna Mantovani; Richard Gordon; Rui Li; Daniel C Christie; Vinod Kumar; Trent M Woodruff
Journal:  Hum Mol Genet       Date:  2016-02-21       Impact factor: 6.150

4.  Selective sparing of a class of striatal neurons in Huntington's disease.

Authors:  R J Ferrante; N W Kowall; M F Beal; E P Richardson; E D Bird; J B Martin
Journal:  Science       Date:  1985-11-01       Impact factor: 47.728

5.  Enhanced striatopallidal gamma-aminobutyric acid (GABA)A receptor transmission in mouse models of huntington's disease.

Authors:  Tamara Perez-Rosello; Simon Gelman; Geoffrey Tombaugh; Roger Cachope; Vahri Beaumont; D James Surmeier
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

6.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.

Authors:  D Dawbarn; M E De Quidt; P C Emson
Journal:  Brain Res       Date:  1985-08-12       Impact factor: 3.252

7.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

8.  Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study.

Authors:  Y P Deng; R L Albin; J B Penney; A B Young; K D Anderson; A Reiner
Journal:  J Chem Neuroanat       Date:  2004-06       Impact factor: 3.052

9.  Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease.

Authors:  Joyce K H Tang; Elena Moro; Neil Mahant; William D Hutchison; Anthony E Lang; Andres M Lozano; Jonathan O Dostrovsky
Journal:  J Neurophysiol       Date:  2007-05-30       Impact factor: 2.714

10.  Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease.

Authors:  S J Sawiak; N I Wood; G B Williams; A J Morton; T A Carpenter
Journal:  Neurobiol Dis       Date:  2008-10-01       Impact factor: 5.996

View more
  5 in total

1.  Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.

Authors:  H Wang; N Del Mar; Y Deng; A Reiner
Journal:  Neurosci Lett       Date:  2021-08-17       Impact factor: 3.197

2.  Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.

Authors:  Sonia Malaiya; Marcia Cortes-Gutierrez; Brian R Herb; Sydney R Coffey; Samuel R W Legg; Jeffrey P Cantle; Carlo Colantuoni; Jeffrey B Carroll; Seth A Ament
Journal:  J Neurosci       Date:  2021-05-19       Impact factor: 6.167

3.  BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington's Disease.

Authors:  Vyshnavi Rallapalle; Annesha C King; Michelle Gray
Journal:  Front Neuroanat       Date:  2021-05-24       Impact factor: 3.856

Review 4.  Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway.

Authors:  Joshua Barry; Minh T N Bui; Michael S Levine; Carlos Cepeda
Journal:  Neurobiol Dis       Date:  2021-11-27       Impact factor: 7.046

5.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.